[Immediate post TURBT MMC instillation.].

Mitomycin C is an antitumor alkylating antibiotic agent that inhibits DNA synthesis extensively used as intravesical chemotherapy agent in the adjuvant treatment of urothelial carcinoma. Its clinical efficacy is the context of single early postoperative instillation was demonstrated by Toley et al. in 1988. Since then, multiple clinical trials and 4 metanalyses have endorsed its use with level 1a evidence. The objective of this chapter is to perform a comprehensive updated review on the use of MMC in the context of single early instillation at the time of TURBT, the available clinical evidence, most relevant recommendations in the international clinical guidelines, its complications and potential maneuvers for the optimization of its use.